Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)

Published:2024-07 Issue:7 Volume:5 Page:101615
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Zhang Chao,Sun Yu-Xuan,Yi Ding-Cheng,Jiang Ben-Yuan,Yan Li-Xu,Liu Ze-Dao,Peng Li-Shan,Zhang Wen-Jie,Sun Hao,Chen Zhi-Yong,Wang Dan-Hua,Peng Di,Chen Song-An,Li Si-Qi,Zhang Ze,Tan Xiao-Yue,Yang Jie,Zhao Zhang-Yi,Zhang Wan-Ting,Su Jian,Li Yang-Si,Liao Ri-Qiang,Dong Song,Xu Chong-Rui,Zhou Qing,Yang Xue-Ning,Wu Yi-Long,Zhang Ze-Min,Zhong Wen-Zhao

Publisher

Elsevier BV

Reference67 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med.,2004

2. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J. Thorac. Oncol.,2014

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

4. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial;Wu;Lancet Oncol.,2017

5. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer;Soria;N. Engl. J. Med.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP